Relmada Therapeutics (Relmada Therapeutics) Cash-to-Debt : No Debt ⁽¹⁾ (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Relmada Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Relmada Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Relmada Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Relmada Therapeutics's Cash-to-Debt or its related term are showing as below:

RLMD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.76 Med: 85.11 Max: No Debt
Current: No Debt

During the past 11 years, Relmada Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 0.76. And the median was 85.11.

RLMD's Cash-to-Debt is ranked better than
99.74% of 1541 companies
in the Biotechnology industry
Industry Median: 6.49 vs RLMD: No Debt

Relmada Therapeutics Cash-to-Debt Historical Data

The historical data trend for Relmada Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Relmada Therapeutics Cash-to-Debt Chart

Relmada Therapeutics Annual Data

Trend

Aug13

Jun15

Jun16

Jun17

Jun18

Jun19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

25.32

No Debt

Relmada Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Relmada Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Relmada Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Relmada Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relmada Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Relmada Therapeutics's Cash-to-Debt falls into.

Relmada Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Relmada Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Relmada Therapeutics had no debt ⁽¹⁾.

Relmada Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Relmada Therapeutics had no debt ⁽¹⁾.

Relmada Therapeutics (NAS:RLMD) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Relmada Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Relmada Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Relmada Therapeutics (Relmada Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relmada Therapeutics Inc (NAS:RLMD) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

4E2:Germany

Address

2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134

Website

https://www.relmada.com

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Executives

Cedric O'gorman	officer: Chief Medical Officer	C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES FL 33134
Fabiana Fedeli	director	C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES FL 33134
Sergio Traversa	director, officer: Chief Executive Officer	138 CANTERBURY LN, BLUE BELL PA 19422
Paul Edward Kelly	director	300 EAST 56TH STREET, APT 19E, NEW YORK, NY 10022
Charles J Casamento	director	99 BELBROOK WAY, ATHERTON CA 94027
Maged Shenouda	director	305 WEST 18TH STREET, APT 4B, NEW YORK NY 10011
Thomas Wessel	officer: EVP, Head of R&D	15 SKYLINE DRIVE, HAWTHORNE NY 10532
Eric Thomas Schmidt	director	C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
John Glasspool	director	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Chuck Ence	officer: Chief Financial Officer	3000 S. UNIVERSITY BLVD., DENVER CO 80210
Ottavio V. Vitolo	officer: Chief Medical Officer	71 WESTLAND AVENUE, NEWTON MA 02465
Shreeram Agharkar	director	P.O BOX 2042, PRINCETON NJ 08543
Sandesh Seth	director	300 E 93RD STREET, #20-B, NEW YORK NY 10128
Lisa Nolan	officer: Chief Business Officer	36 ROCKLAND MILLS, ROCKLAND DE 19732
Eliseo Oreste Salinas	officer: President and CSO	7707 GATEWAY BLVD, NEWARK CA 94560